Xuanzhu Biopharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Xuanzhu Biopharmaceutical Co., Ltd.
Oncology Developer Yahong Bags China’s First Biotech IPO Of 2022
Jiangsu Yahong and 11 Chinese biotechs raised a combined $1.1bn via public listings and VC/PE deals in the run-up to and first week of the new year.
Asia Deal Watch: Hansoh Teams Up With OliX On SIRNA Therapies
Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.